Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
BlackRock, Inc. has filed Amendment No. 4 to Schedule 13G revealing a 5,950,909-share position in Artivion, Inc. (AORT) as of 30 June 2025. The stake equals 13.9 % of the outstanding common stock, giving BlackRock sole voting authority over 5,884,199 shares and sole dispositive authority over all 5,950,909 shares; no shared authority is reported.
The disclosure is made pursuant to Rule 13d-1(b) with BlackRock classified as a parent holding company/control person (HC). Management certifies the shares are held in the ordinary course, without intent to influence control. The filing notes that the iShares Core S&P Small-Cap ETF, a BlackRock vehicle, independently owns more than 5 % of Artivion’s float.
A double-digit passive stake from the world’s largest asset manager enhances Artivion’s institutional ownership base and may support liquidity, but the absence of activist language suggests no immediate strategic impact.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
What is the primary focus of Artivion, Inc.?
Which product categories does Artivion offer?
How does Artivion support surgical procedures?
What role do clinical trials play in Artivion's strategy?
In which markets does Artivion operate?
How does Artivion differentiate itself from competitors?
What are some key benefits of using Artivion’s devices?
How is Artivion enhancing its product development?
